tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MetaVia Partners with Syntekabio for DA-1241 Research

Story Highlights
MetaVia Partners with Syntekabio for DA-1241 Research

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest announcement is out from MetaVia ( (MTVA) ).

On August 4, 2025, MetaVia Inc. announced a research collaboration with Syntekabio, Inc. to explore additional indications for DA-1241, a novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. This partnership aims to leverage Syntekabio’s AI-driven DeepMatcher® platform to optimize DA-1241’s therapeutic profile and identify new disease targets. This collaboration follows positive results from a Phase 2a study of DA-1241, which showed favorable safety and efficacy in MASH patients. The initiative is expected to enhance MetaVia’s industry positioning by expanding the drug’s therapeutic potential, potentially addressing a range of unmet medical needs.

The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.

Spark’s Take on MTVA Stock

According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.

MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.

To see Spark’s full report on MTVA stock, click here.

More about MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Average Trading Volume: 263,020

Technical Sentiment Signal: Sell

Current Market Cap: $11.93M

Learn more about MTVA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1